About Us

SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies. Read More...

A UNIQUE WAY OF DISCOVERING DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS


 

COMBINING INNOVATIVE BIOMARKER WITH OUTSTANDING TECHNOLOGY

Sphingotec GmbH Logo
NexusDX

 

LATEST NEWS

 

  • SphingoTec, BHR Pharmaceuticals ink agreement for distribution of SphingoTec’s acute care portfolio in the UK and Ireland

    SphingoTec, BHR Pharmaceuticals ink agreement for distribution of SphingoTec’s acute care portfolio in the UK and Ireland

  • SphingoTec’s kidney function biomarker penKid® accurately detects acute kidney injury in infants

    SphingoTec’s kidney function biomarker penKid® accurately detects acute kidney injury in infants

  • SphingoTec Issues Convertible Note Facility

    SphingoTec Issues Convertible Note Facility

  • SphingoTec to Present at the Solebury Trout’s Summer Private Company Showcase

    SphingoTec to Present at the Solebury Trout’s Summer Private Company Showcase

 

BIOMARKER

 

Sphingotest penKid
sphingotest® penKid®
Sphingotest bio-ADM
sphingotest® bio-ADM®

 
 

A UNIQUE WAY OF DISCOVERING DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS

 

 

 

Top